Noxopharm CEO Discusses Sofra Cancer Platform

Why It Matters

The Sofra platform could transform treatment of inflammatory and cancer diseases while providing a near‑term catalyst that may dramatically increase Noxopharm’s market value for investors.

Key Takeaways

• Noxopharm's RNA‑based platform modulates immune receptors for inflammation
• First product, Sofra cream, targets cutaneous lupus via dermal delivery
• Phase‑1 showed safety; efficacy proof‑of‑concept data pending in patients
• Platform aims to treat autoimmune, cancer, and organ‑specific diseases
• CEO expects catalysts and share‑price surge within six‑nine months

Summary

Noxopharm CEO Olivier Lasker outlined the company’s Sofra platform, an RNA‑based drug suite designed to modulate immune‑receptor activity. The technology, built on a seven‑year discovery of endogenous immune regulation, aims to either dampen or amplify inflammation, depending on the disease context.

The first clinical candidate is a topical cream for cutaneous lupus, delivered directly to the dermis to suppress local immune receptors without systemic exposure. Phase‑1 trials demonstrated safety and tolerability, and the company now seeks proof‑of‑concept efficacy signals. Parallel delivery strategies—including inhaled formulations for lung inflammation and targeted carriers for joints or tumors—are being pursued through partnerships.

Lasker emphasized that the skin acts as a “sanctuary” for immune cells, allowing the cream to act locally while avoiding the immunosuppression associated with steroids. He highlighted ongoing collaborations with European and U.S. firms to deliver the small‑RNA payload to various organs, and noted early animal data showing reduced inflammation in lungs.

If efficacy is confirmed, the platform could address a broad spectrum of autoimmune, metabolic and oncology indications, attracting pharma interest and potentially driving a rapid share‑price uplift within the next six to nine months as the company moves toward larger trials.

Original Description

Noxopharm Limited CEO Olivier Laczka talked with Proactive about the company's Sofra™ technology platform and how its discovery around Toll-like receptor 8 (TLR8) could unlock new opportunities in cancer treatment and chronic inflammatory diseases.

Laczka explained how Noxopharm has spent years developing a deeper understanding of the body's immune system and the mechanisms that regulate inflammation. Through research conducted alongside scientists at the Hudson Institute of Medical Research, the company identified a novel way to modulate immune responses using small RNA-based oligonucleotides.

The company is initially advancing a topical treatment for cutaneous lupus, designed to target inflammation directly in the skin while avoiding systemic immunosuppression. According to Laczka, this approach could provide a significant advantage over current treatments such as corticosteroids, which can carry substantial side effects with prolonged use.

Beyond autoimmune disease, Noxopharm is also developing applications in immuno-oncology. The company recently announced data showing that Sofra-derived oligonucleotides can significantly amplify the activity of TLR8, a key immune receptor being targeted in cancer therapies. New studies demonstrated that a proprietary TLR8-amplifying oligonucleotide boosted the activity of a clinical-stage TLR8 agonist by more than 200-fold in human skin biopsies.

The interview also covers upcoming clinical milestones, strategic collaborations, delivery technologies and the company's plans to generate efficacy data in patients over the coming months.

For more interviews and market insights, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content.

#Noxopharm #NOX #ASXNOX #Biotech #Immunotherapy #CancerResearch #CancerTreatment #ImmunoOncology #TLR8 #Sofra #RNAtherapeutics #Oligonucleotides #DrugDevelopment #HealthcareInnovation #LupusResearch #Inflammation #Biotechnology #ASXStocks #ProactiveInvestors #ClinicalTrials